FidoCure

What FidoCure does

FidoCure, operated by One Health Company, Inc. and headquartered in Palo Alto, California, is a veterinary health technology company that applies AI-driven precision medicine to canine cancer. Its core product combines DNA sequencing of canine tumor tissue at a CLIA-certified laboratory with machine learning analysis of the largest proprietary canine cancer clinico-genomic dataset in the world (2 billion data points from thousands of sequenced and longitudinally followed dogs) to identify cancer-driving mutations and recommend targeted therapies matched to each dog's tumor profile. A streamlined Therapy Only Service provides expedited access to targeted therapies for cancers with known biomarkers (c-Kit-driven mast cell tumors, BRAF+ transitional cell carcinoma), and veterinarians access results and clinical guidance through a dedicated DVM portal (dvm.fidocure.com) with telemedicine support from the company's medical affairs team.

The company serves three primary stakeholders: pet parents seeking treatment options beyond standard chemotherapy and radiation for dogs with cancer, veterinarians and veterinary oncologists seeking advanced precision-medicine tools to differentiate their practice, and (secondarily) human biopharmaceutical companies that use FidoCure's comparative oncology dataset for drug R&D, biomarker discovery, and clinical-trial proof-of-concept studies. To date, FidoCure has guided treatment for over 6,000 dogs and works with 1,300+ veterinary clinics and oncology specialists across 32 US states. Targeted therapies are dispensed through partner compounding pharmacies that ship within 3–5 business days, leveraging AMDUCA to legally repurpose FDA-approved human drugs for extra-label canine use.

FidoCure generates revenue primarily by invoicing veterinarians for the one-time DNA sequencing diagnostic and by facilitating transactions for targeted therapies through partner compounding pharmacies (typically billed separately). Pricing is not publicly disclosed and varies by clinic; the service is covered by most pet insurance companies. GTM combines direct field engagement by a veterinary affairs team with a self-serve DVM portal and content-led adoption via case studies, webinars, and peer-reviewed publications. The company is VC-backed (a16z, Y Combinator, Polaris Partners, Lerer Hippeau, Tau Ventures, and others) and has published multiple studies in Nature-family journals, including a 2025 Nature Scientific Reports paper demonstrating up to a 50% reduction in risk of death for hemangiosarcoma patients treated with the precision medicine approach.

Name

FidoCure

Legal name

One Health Company, Inc.

Website

https://fidocure.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

FidoCure, operated by One Health Company, is a Palo Alto-based veterinary health technology company that applies AI-driven precision medicine and DNA sequencing to deliver personalized targeted therapies for canine cancer, serving pet parents and 1,300+ veterinary clinics across 32 US states.

Ownership category

akta.pro rank

Product category

Veterinary Precision Oncology

NAICS

Medical Laboratories (621511), Veterinary Services (541940), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)

akta.pro primary industry

Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology) (HLAMADAE)

akta.pro secondary industries

Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry) (HLAMADAJ), Tele-veterinary & Virtual Care Platforms (Video/Chat, Remote Triage) (HLAMAGAB), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Canine cancer treatment
• Veterinary genomic testing
• Precision medicine
• DNA sequencing services
• Targeted cancer therapy

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. DNA Sequencing Diagnostic Testing: FidoCure invoices veterinarians for genomic testing services. Tissue samples are submitted for DNA sequencing at a CLIA certified lab, generating a personalized DNA report identifying genetic mutations.
2. Targeted Therapy Access Facilitation: FidoCure facilitates access to FDA-approved human targeted therapies through a network of partner compounding pharmacies. The company enables veterinarians to prescribe and order therapies based on genetic test results. FidoCure does not directly supply drugs but connects pet parents with pharmacy partners.
3. Therapy Only Service: For certain cancers like mast cell tumors (c-Kit driven) and transitional cell carcinomas (BRAF+), veterinarians can receive expedited access to specific targeted therapies without full genomic sequencing.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

FidoCure, developed by One Health Company, provides genomic DNA sequencing of canine tumor tissue at a CLIA-certified laboratory to identify cancer-driving mutations, then recommends FDA-approved targeted therapies that veterinarians can prescribe. The service combines genomic testing with tumor profiling and AI-driven therapeutic matching, and includes telemedicine-enabled clinical guidance for prescribing veterinarians and facilitated access to compounded targeted therapies through partner pharmacies.

Product overview

FidoCure is a comprehensive canine cancer care service developed by One Health Company that provides genomic testing and personalized targeted therapy recommendations for dogs with cancer. The core offering consists of DNA Sequencing & Targeted Therapy, which sequences tumor DNA at CLIA-certified labs to identify mutations and recommend targeted treatments. An optional Therapy Only Service provides expedited access for known biomarker-driven cancers like mast cell tumors and transitional cell carcinoma. Veterinarians access results and manage patients through a dedicated Veterinary Portal with telemedicine support. The platform is powered by AI and real-world evidence from the largest canine cancer clinico-genomic dataset in the world, enabling personalized treatment recommendations beyond traditional chemotherapy and radiation.

Differentiator

Problem solved

Functional benefit

Products and services

• FidoCure DNA Sequencing & Targeted Therapy A comprehensive genomic testing service for canine cancer that sequences tumor DNA at a CLIA-certified laboratory, generates a personalized DNA report identifying cancer-driving mutations, and recommends targeted therapies for veterinarians to prescribe. It is offered to veterinary clinics and oncology specialists who bill pet parents.
• FidoCure Therapy Only Service A standalone service for cases such as mast cell tumors (c-Kit driven) and transitional cell carcinoma (BRAF+) that provides expedited data-based reports and therapy access without full genomic sequencing, leveraging known biomarkers to enable faster targeted therapy initiation.

Quantifiable outcome

• Dogs with hemangiosarcoma may experience up to 50% reduced risk of death using precision medicine approach
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core.

• Fetch AIcoreTechnology or IntegrationPartnership for analyzing and confirming the real-world effectiveness of FidoCure's precision medicine approach using AI technology at scale.
• EisaicoreStrategic or Co-development PartnerOne Health canine data helped Eisai drug reach Phase 2 at Mass General Hospital, demonstrating the value of canine comparative oncology for human drug development.
• Stanford UniversitycoreStrategic or Co-development PartnerAcademic collaboration on peer-reviewed research in canine cancer genomics and precision medicine.
• Broad Institute of MIT and HarvardcoreStrategic or Co-development PartnerResearch collaboration on genomic alterations in canine cancer, particularly hemangiosarcoma studies.
• Tufts UniversitycoreStrategic or Co-development PartnerCollaborative research on precision medicine tools for understanding hemangiosarcoma in dogs.
• University of Georgia College of Veterinary MedicinecoreStrategic or Co-development PartnerAcademic partnership for advancing canine cancer research and treatment outcomes.
• Partner Compounding PharmaciescoreChannel Partner/ Reseller/ DistributorLicensed and Board of Pharmacy inspected facilities preparing targeted therapies from human-grade APIs sourced from FDA-registered repackagers. Therapies are compounded and shipped within 3-5 business days.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Antech Diagnostics (Mars Petcare): Antech is the second-largest veterinary reference lab network in North America, owned by Mars Petcare, and operates adjacent pet genetics and wellness screening products. It competes indirectly via clinic-level diagnostics bundling.
• IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company with broad reference lab, in-clinic analyzer, and software offerings, and now owns PetDx. It is the most likely well-capitalized incumbent to bundle canine genomic oncology into its clinic stack.
• Zoetis: Zoetis is the largest global animal health company, spanning pharma, diagnostics, and genetics (via its acquisition of Basepaws and Wisdom Panel). It represents the broadest incumbent threat across FidoCure's verticals.
• Wisdom Panel (Mars Petcare): Wisdom Panel is the leading direct-to-consumer dog breed and health genetics test, owned by Mars Petcare. It is comparable as a canine genomics consumer brand, though its clinical oncology depth is shallow relative to FidoCure.

Emerging players

• Embark Veterinary: Embark offers direct-to-consumer dog DNA testing for breed, traits, and health risks. It overlaps with FidoCure on the canine genomics infrastructure but serves consumer breed/health screening rather than oncology therapeutic matching.

Direct peers

• PetDx: PetDx (now part of IDEXX) developed a liquid biopsy test (OncoK9) for early cancer detection in dogs using next-generation sequencing. It is the most direct competitor in canine genomic oncology diagnostics, although FidoCure focuses on therapeutic matching rather than screening.
• Anivive Lifesciences: Anivive is a veterinary pharma and biotech company developing novel therapeutics for companion animal cancers and infectious diseases. It overlaps with FidoCure on the canine oncology drug-access value chain.
• Torigen Pharmaceuticals: Torigen develops autologous cancer immunotherapies (Versinia) for companion animals, sold directly to veterinary clinics. It competes for the same veterinary oncology dollar via a different therapeutic modality.
• VetDC (now Elanco): VetDC developed Tanovea, a novel chemotherapy for canine lymphoma, and was acquired by Elanco. It is a direct comparator in the canine oncology therapeutics space that FidoCure occupies.
• Ardent Animal Health: Ardent Animal Health provides advanced veterinary specialty services including oncology, internal medicine, and surgery across multiple clinics. It represents an alternate channel through which canine oncology demand is currently served.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/fidocure
• Facebookfacebook.com/FidoCure
• Instagraminstagram.com/fidocure
• Pinterestpinterest.com/fidocure

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FidoCure